DoD Neurofibromatosis Clinical Trial Award

archived

The vision of the FY13 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; foster the next generation of NF investigators; promote translational and clinical studies to move promising ideas from bench to bedside; develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. Areas of Emphasis: The FY13 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the following Areas of Emphasis: • Cognitive and social dysfunction in the setting of NF; • Drug discovery for the treatment of NF; • Heterogeneity of neurofibromas and other NF-related tumors using genomics, epigenetics, systems biology, or other similar approaches; • Manifestations of NF post-adolescence; • Novel disease markers such as imaging and proteomics of NF; • Pain in the setting of NF. The NFRP Clinical Trial Award supports clinical trials with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising DoD FY13 NFRP Clinical Trial Award 4 new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first in human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies.

High